Skip to main content
. Author manuscript; available in PMC: 2022 Mar 25.
Published in final edited form as: Am J Prev Med. 2020 Nov 20;60(3):411–414. doi: 10.1016/j.amepre.2020.09.013

Table 2.

Summary of Immunization and Preventive Care Measures for Adolescents Reported by HEDIS, Stratified by States’ Use of HEDIS and HPA

Measures from HEDIS Use either HEDIS or HPA Use neither HEDIS nor HPA Comparison
Mean % (SD) 25th percentile 75th percentile Mean % (SD) 25th percentile 75th percentile Mean difference p-value
Vaccinations
 HPV 27.2 (8.5) 21.7 30.5 29.1 (9.7) 22.4 34.0 −1.9 0.139
 Meningococcal 81.9 (9.3) 76.7 88.8 77.0 (9.2) 70.9 84.3 5.0 <0.001 ***
 Tdap 88.0 (7.5) 85.9 93.2 85.4 (7.3) 80.4 90.8 2.7 0.008 ***
Access/utilization of preventive care
 Well-care visits 50.9 (12.1) 42.8 58.2 45.4 (9.3) 38.7 52.1 5.5 <0.001 ***
 Access to PCP 90.8 (4.5) 88.4 93.8 89.4 (3.77) 87.91 92.07 1.3 0.012 **
Number of states 32 7
Number of companies 292 63

Note: Boldface indicates statistical significance.

**

p<0.05,

***

p<0.01

The analysis included 39 states that have at least 70% of public reporting. The District of Columbia is not a U.S. state, but the term state is used for simplicity. States identified as using HEDIS or HPA (HEDIS/HPA) included Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, and Wisconsin. States identified as not using HEDIS/HPA included Colorado, Delaware, District of Columbia, Idaho, Kansas, North Carolina, and Washington.

HEDIS, Health Effectiveness Data and Information Set; HPA, Health Plan Accreditation; HPV, human papillomavirus; PCP, primary care practitioner; Tdap, tetanus, diphtheria, and acellular pertussis vaccine.